In a recently published study, we used simulations to compare statistical validity and power for an SWCT and a STRIVE-like RCT in the same trial population. 3 Piszczek and Parlow 1 contend that an SWCT can achieve greater statistical power than an RCT by many beforeand-after and between-group comparisons; however, we found that the declining and heterogeneous epidemic incidence across Sierra Leone undermines such cluster-level comparisons and, consequently, the power of an SWCT. Specifically, we estimated that the SWCT design would be three to ten times less likely than an individually randomised, phased roll-out RCT to definitively identify an efficacious vaccine. For example, an SWCT starting in April 2015 was expected to have a less than 10% chance of detecting the eff ect of a 90% effi cacious vaccine.
As emphasised by Piszczek and Parlow 1 (and the article to which they respond 4 ), the primary advantage of an SWCT is that it avoids the ethical problem of withholding a potentially life-saving intervention from trial participants. Phased roll-out RCTs can address this shortcoming, in part, by vaccinating all control participants at the end of the trial, as in STRIVE, although this introduces a delay in vaccination of some participants in the interest of experimental design. When risk is highly variable in space and time, as with Ebola in Sierra Leone, however, a phased roll-out RCT has an additional ethical advantage the SWCT lacks: it allows prioritised vaccination of clusters experiencing high infection risk. Such prioritisation would confer the highest likelihood of benefit to those at highest risk, thereby reducing the total risk to trial participants relative to a non-risk-prioritised design. By contrast, an SWCT needs random-ordered roll-out by defi nition 5 and therefore cannot allow such prioritisation. An observational impact assessment of risk-prioritised vaccine roll-out without a control group would produce biased effi cacy estimates, since vaccination order Syed Ather Hussain, Mohammed Madadin, *Ritesh G Menezes
